^
    18h
    Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide
    21h
    ZM008-001: This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=100, Recruiting, Zumutor Biologics Inc. | N=33 --> 100
    Enrollment change
    |
    Loqtorzi (toripalimab-tpzi) • ZM008
    23h
    Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients (clinicaltrials.gov)
    P2, N=41, Completed, Fudan University | Active, not recruiting --> Completed
    Trial completion
    |
    Erbitux (cetuximab) • cisplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel
    24h
    Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=60, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New trial
    1d
    ILLUMINE: Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN (clinicaltrials.gov)
    P3, N=780, Not yet recruiting, Groupe Oncologie Radiotherapie Tete et Cou
    Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yidafan (ivonescimab) • ligufalimab (AK117)
    1d
    Single-cell analysis highlights the significance of malignant cell IFN/MHC-II for immunotherapy response in head and neck squamous cell carcinoma. (PubMed, Cell Rep Med)
    Here, we perform single-cell RNA sequencing (RNA-seq) on 16 HNSCC patients pre- and post-neoadjuvant pembrolizumab treatment...Finally, we confirm that pre-treatment malignant-IFN/MHC-II is a marker of response through deconvolution of bulk RNA-seq data from an independent cohort. Beyond identifying the malignant IFN/MHC-II program as a potential biomarker for immunotherapy response in HNSCC, our work elucidates the important role of malignant cells in immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Keytruda (pembrolizumab)
    1d
    Successful management of near-infrared photoimmunotherapy-induced skin injury using pedicled flap transfer. (PubMed, Auris Nasus Larynx)
    Currently, NIR-PIT is approved only in Japan for the treatment of unresectable, locally recurrent head and neck squamous cell carcinoma, using the anti-epidermal growth factor receptor antibody cetuximab and the photoabsorber IR700...After confirming the absence of tumor recurrence, the patient was successfully treated using a well-vascularized pedicled flap. This case highlights two key management considerations for NIR-PIT-induced skin injury: surgical indications and cancer treatment. Further studies are necessary to improve the management of severe skin complications following NIR-PIT.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    Erbitux (cetuximab)
    2d
    NL74742.078.20: The STELLAR trial: Fluorescence-guided surgery in laryngeal- and hypopharyngeal cancer: a feasibility trial (2024-519750-36-00)
    P1/2, N=27, Recruiting, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Not yet recruiting --> Recruiting
    Enrollment open
    2d
    BD4QoL: Big Data for Quality of Life in Head and Neck Cancer (clinicaltrials.gov)
    P=N/A, N=410, Completed, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Recruiting --> Completed | Trial completion date: Jun 2025 --> Oct 2025 | Trial primary completion date: Sep 2024 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date • HEOR
    2d
    Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC (clinicaltrials.gov)
    P2, N=35, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Recruiting | N=25 --> 35 | Trial completion date: Nov 2026 --> May 2027 | Trial primary completion date: Nov 2026 --> May 2027
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    2d
    DB-1310-O-1001: A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=1000, Recruiting, DualityBio Inc. | Trial completion date: Aug 2026 --> Apr 2028 | Trial primary completion date: Aug 2026 --> Dec 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    Herceptin (trastuzumab) • Tagrisso (osimertinib) • capecitabine • DB-1310
    2d
    NCI-2022-02855: Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, Emory University | Trial completion date: May 2026 --> Jan 2028
    Trial completion date